Is Roivant Sciences Stock a Good Investment?
Roivant Sciences Investment Advice | ROIV |
- Examine Roivant Sciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Roivant Sciences' leadership team and their track record. Good management can help Roivant Sciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Roivant Sciences' business and its evolving consumer preferences.
- Compare Roivant Sciences' performance and market position to its competitors. Analyze how Roivant Sciences is positioned in terms of product offerings, innovation, and market share.
- Check if Roivant Sciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Roivant Sciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Roivant Sciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Roivant Sciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Roivant Sciences Stock
Researching Roivant Sciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 31.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Roivant Sciences recorded a loss per share of 0.75. The entity had not issued any dividends in recent years.
To determine if Roivant Sciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Roivant Sciences' research are outlined below:
| The company reported the previous year's revenue of 29.05 M. Net Loss for the year was (356.73 M) with loss before overhead, payroll, taxes, and interest of (516.47 M). | |
| Roivant Sciences currently holds about 1.94 B in cash with (839.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Roivant Hosts Investor Webinar on Brepocitinibs Role in Dermatomyositis ROIV Stock News |
Roivant Sciences Quarterly Long Term Debt |
|
Roivant Sciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Roivant Sciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Roivant Sciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 26th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Roivant Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Roivant Sciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-11 | 2024-12-31 | -0.24 | -0.1988 | 0.0412 | 17 | ||
2022-06-28 | 2022-03-31 | -0.32 | -0.27 | 0.05 | 15 | ||
2024-11-12 | 2024-09-30 | -0.26 | -0.313 | -0.053 | 20 | ||
2025-05-29 | 2025-03-31 | -0.1633 | -0.2183 | -0.055 | 33 | ||
2023-08-14 | 2023-06-30 | -0.3 | -0.38 | -0.08 | 26 | ||
2023-11-13 | 2023-09-30 | -0.31 | -0.4 | -0.09 | 29 | ||
2023-02-13 | 2022-12-31 | -0.39 | -0.49 | -0.1 | 25 | ||
2021-11-15 | 2021-09-30 | -0.22 | -0.32 | -0.1 | 45 |
Roivant Sciences Target Price Consensus
Roivant target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Roivant Sciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Roivant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Roivant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Roivant Sciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRoivant Sciences Target Price Projection
Roivant Sciences' current and average target prices are 11.44 and 16.75, respectively. The current price of Roivant Sciences is the price at which Roivant Sciences is currently trading. On the other hand, Roivant Sciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Roivant Sciences Market Quote on 18th of June 2025
Target Price
Analyst Consensus On Roivant Sciences Target Price
Roivant Sciences Analyst Ratings
Roivant Sciences' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Roivant Sciences stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Roivant Sciences' financials, market performance, and future outlook by experienced professionals. Roivant Sciences' historical ratings below, therefore, can serve as a valuable tool for investors.Know Roivant Sciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Roivant Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Roivant Sciences backward and forwards among themselves. Roivant Sciences' institutional investor refers to the entity that pools money to purchase Roivant Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Amvescap Plc. | 2025-03-31 | 9.9 M | Geode Capital Management, Llc | 2025-03-31 | 8 M | Ubs Group Ag | 2024-12-31 | 5.3 M | Woodline Partners Lp | 2025-03-31 | 5.3 M | Anchorage Advisors, Llc | 2025-03-31 | 4.8 M | Blackbarn Capital Partners Lp | 2025-03-31 | 4.8 M | Norges Bank | 2024-12-31 | 4.4 M | Toms Capital Investment Management Lp | 2025-03-31 | 4.1 M | Bank Of New York Mellon Corp | 2025-03-31 | 4 M | Qvt Financial Lp | 2025-03-31 | 65.8 M | Sb Investment Advisers (uk) Ltd | 2025-03-31 | 61.9 M |
Roivant Sciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.55 B.Market Cap |
|
Roivant Sciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.19) | (0.20) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Determining Roivant Sciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Roivant Sciences is a good buy. For example, gross profit margin measures Roivant Sciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Roivant Sciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Roivant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roivant Sciences. Check Roivant Sciences' Beneish M Score to see the likelihood of Roivant Sciences' management manipulating its earnings.
Evaluate Roivant Sciences' management efficiency
Roivant Sciences has return on total asset (ROA) of (0.1073) % which means that it has lost $0.1073 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1254) %, meaning that it created substantial loss on money invested by shareholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.03 in 2025. Return On Capital Employed is likely to drop to -0.2 in 2025. At this time, Roivant Sciences' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 443.1 M in 2025, whereas Other Current Assets are likely to drop slightly above 83.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.47 | 5.83 | |
| Tangible Book Value Per Share | 9.27 | 5.75 | |
| Enterprise Value Over EBITDA | 2.38 | 2.50 | |
| Price Book Value Ratio | 1.23 | 2.04 | |
| Enterprise Value Multiple | 2.38 | 2.50 | |
| Price Fair Value | 1.23 | 2.04 | |
| Enterprise Value | 1.9 B | 2.1 B |
The operational strategies employed by Roivant Sciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 1.164 |
Basic technical analysis of Roivant Stock
As of the 18th of June 2025, Roivant Sciences holds the Coefficient Of Variation of 2621.71, risk adjusted performance of 0.0656, and Semi Deviation of 1.99. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Roivant Sciences, as well as the relationship between them. Please check Roivant Sciences coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Roivant Sciences is priced some-what accurately, providing market reflects its current price of 11.44 per share. Given that Roivant Sciences has jensen alpha of 0.0845, we recommend you to check out Roivant Sciences's recent market performance to make sure the company can sustain itself at a future point.Roivant Sciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Roivant Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roivant Sciences' Outstanding Corporate Bonds
Roivant Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Roivant Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Roivant bonds can be classified according to their maturity, which is the date when Roivant Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Roivant Sciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Roivant Sciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0656 | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 1.74 | |||
| Semi Deviation | 1.99 | |||
| Downside Deviation | 2.04 | |||
| Coefficient Of Variation | 2621.71 | |||
| Standard Deviation | 2.34 | |||
| Variance | 5.48 | |||
| Information Ratio | 0.0274 | |||
| Jensen Alpha | 0.0845 | |||
| Total Risk Alpha | 0.0578 | |||
| Sortino Ratio | 0.0315 | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 13.33 | |||
| Value At Risk | (2.79) | |||
| Potential Upside | 3.35 | |||
| Downside Variance | 4.17 | |||
| Semi Variance | 3.96 | |||
| Expected Short fall | (1.88) | |||
| Skewness | 0.8834 | |||
| Kurtosis | 2.65 |
| Risk Adjusted Performance | 0.0656 | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 1.74 | |||
| Semi Deviation | 1.99 | |||
| Downside Deviation | 2.04 | |||
| Coefficient Of Variation | 2621.71 | |||
| Standard Deviation | 2.34 | |||
| Variance | 5.48 | |||
| Information Ratio | 0.0274 | |||
| Jensen Alpha | 0.0845 | |||
| Total Risk Alpha | 0.0578 | |||
| Sortino Ratio | 0.0315 | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 13.33 | |||
| Value At Risk | (2.79) | |||
| Potential Upside | 3.35 | |||
| Downside Variance | 4.17 | |||
| Semi Variance | 3.96 | |||
| Expected Short fall | (1.88) | |||
| Skewness | 0.8834 | |||
| Kurtosis | 2.65 |
Consider Roivant Sciences' intraday indicators
Roivant Sciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Roivant Sciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Roivant Sciences Corporate Filings
F4 | 6th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify | |
| 25th of February 2025 Other Reports | ViewVerify |
Roivant Stock media impact
There is far too much social signal, news, headlines, and media speculation about Roivant Sciences that are available to investors today. This information is accessible both publicly - through Roivant Sciences' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Roivant-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Roivant Sciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Roivant Sciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Roivant Sciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Roivant Sciences alpha.
Roivant Sciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Roivant Sciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Roivant Sciences Historical Investor Sentiment
Investor biases related to Roivant Sciences' public news can be used to forecast risks associated with an investment in Roivant. The trend in average sentiment can be used to explain how an investor holding Roivant can time the market purely based on public headlines and social activities around Roivant Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Roivant Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Roivant Sciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Roivant Sciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Roivant Sciences.
Roivant Sciences Corporate Management
| Amy Mahery | Chief Officer | Profile | |
| Matthew Gline | CEO Director | Profile | |
| Marianne Romeo | Head Management | Profile | |
| Huafeng Xu | Chief Officer | Profile | |
| Josh Chen | General Counsel | Profile | |
| Matt Maisak | Chief Platforms | Profile | |
| Vivek Ramaswamy | Founder Chairman | Profile |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.